Aline THOMAS

Projets

• Drug design rationnel et cibles thérapeutiques complexes. Certaines cibles thérapeutiques sont complexes à modéliser, et nécessitent une expertise et des méthodes de calcul avancées. Leur étude requiert des associations innovantes entre chimie médicinale, RMN et calculs théoriques. L'objectif du projet est le développement de nouveaux inhibiteurs de métalloenzymes, d'interactions protéine-protéine, ou de multiples cibles, conçus de manière rationnelle.

Publications

• Article • Interest of novel N-alkylpyridinium-indolizine hybrids in the field of Alzheimer’s disease: Synthesis, characterization and evaluation of antioxidant activity, cholinesterase inhibition, and amyloid fibrillation interference [Full paper ]

  I. Baussanne, O. Firstova, A. Botezatu Dediu, C. Larosa, B. Furdui, I. Ottilia Ghinea, A. Thomas, S. Chierici, R. Dinica, M. Demeunynck

  Bioorg. Chem. 2021, 116, 105390

• Article • Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2 [Full paper ]

  E. Roussel, A. Moréno, N. Altounian, C. Philouze, B. Pérès, A. Thomas, O. Renaudet, P. Falson, A. Boumendjel

  Eur. J. Med. Chem. 2020, 202, 112503

• Article • Chimeric Protein-Protein Interface Inhibitors Allow Efficient Inhibition of Type III Secretion Machinery and Pseudomonas aeruginosa Virulence [Full paper ]

  Ngo, T.-D.; Plé, S.; Thomas, A.; Barette, C.; Fortuné, A.; Bouzidi, Y.; Fauvarque, M.-O.; Pereira de Freitas, R.; Francisco Hilário, F.; Attrée, I.; Wong, Y.-S.; Fraudry, E.

  ACS Infect. Dis.

• Patent • Leurre GD-FXa mutant  

  Dagher, M. C., Thomas, A., Marlu, R., Ersayin, A., Polack, B.

  2017 • 

• Article • Catalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex vivo coagulation in hemophilia 

  Ersayin A., Thomas A., Seyve L., Thielens N., Castellan M., Marlu R., Polack B., Dagher M-C.

  Haematologica 2017, 102, e483

• Article • Structural insights and membrane binding properties of MGD1, the major galactolipid synthase in plants.  

  Rocha J., Sarkis J., Thomas A., Pitou L., Radzimanowski J., Audry M., Chazalet V., de Sanctis D., Palcic M., Block M., Girard-Egrot A., Maréchal E., Breton C.

  The Plant Journal, 85(5), 622-33

• Article • Probing the acceptor active site organization of the human recombinant β1,4-galactosyltransferase 7 and design of xyloside-based inhibitors. [Full paper ]

  Saliba M, Ramalanjaona N, Gulberti S, Bertin-Jung I, Thomas A, Dahbi S, Lopin-Bon C, Jacquinet JC, Breton C, Ouzzine M, Fournel-Gigleux S

  J. Biol. Chem. 290, 7658-70

• Patent • Facteur X dépourvu de domain GLA  

  A. Thomas, M-C. Dagher, R. Marlu, B. Polack

  2013 • 

• Patent • Protocoagulant pour hémophile  

  A. Thomas & B. Polack

  2011 • 

• Article • Toward non-factor therapy in hemophilia: an antithrombin insensitive Gla-domainless factor Xa as tissue factor pathway inhibitor bait [Full paper ]

  M.-C. Dagher, A. Ersayin, L. Seyve, M. Castellan, C. Moreau, L. Choisnard, N. Thielens, R. Marlu, B. Polack, A. Thomas

  Res. Practice Thrombosis Haemostasis 2023, 7, 102175

• Article • Could we expect new praziquantel derivatives? A meta pharmacometrics/pharmacoinformatics analysis of all antischistosomal praziquantel derivatives found in the literature [Full paper ]

  V.B. Ribeiro da Silva, B. Boucherle, J. El-Methni, B. Hoffmann, A.L. da Silva, A. Fortune, M. do Carmo Alves de Lima, A. Thomas

  SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2019, VOL. 30, NO. 6, 383–401